Next Phase Newsletter

A global leader in life sciences, diagnostics and applied chemical markets providing services, equipment, and support solutions to laboratories worldwide has an Early Stage Partnership Program that works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit the firm’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.

The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Cellular Reprogramming, Cellular Manufacturing/Bioprocessing, Data Analytics, Informatics, Molecular Diagnostics, Omics, Single Cell Analysis and Systems Biology. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.

The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Headquartered in China, a publicly traded corporation (SHA:600535) is dedicated to building a top-tier, modern, and international brand in pharmaceutical products. The firm provides modernized traditional Chinese medicines (TCMs), small molecule and biological drugs. The firm is actively pursuing strategic partnerships with pharmaceutical companies and bio-techs from domestic and overseas in the abovementioned therapeutic areas. The firm considers a board range of strategies including strategic investment, joint venture, acquisition, licensing, and co-development.

The firm is looking for strategic partnerships in chemical drugs and biological drugs. The firm is open to products at clinical to launched stages in therapeutic areas of cardiovascular, cerebrovascular diseases, oncology, diabetes, liver disease and so on.

The firm is looking to build collaborative partnerships with experienced teams in key strategic sectors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based investment firm is currently investing in early stage biotechnology companies and company creation/spinout/licensing opportunities from dedicated capital. These investments are typically standalone and/or syndicated with a network of investors that have invested with the firm in the past. The firm founds 1-2 companies per year by creating a company around an asset that they acquired or in-licensed. The firm also considers investments in 0-2 existing companies per year, which are typically early in the company’s development and/or follow-on investments. The firm invests globally but requires the company or development programs have a North America component.

The firm is a flexible and opportunistic investor and will consider any therapeutics area, primarily in specialty areas of medicine with a focus on niche areas of medicine and smaller indications, including rare orphan diseases. The firm focuses on drug development and makes occasional investments in therapeutic devices. The firm focuses on clinical stage drug development opportunities, but may consider earlier stage products if the drug is a repositioning/reformulation opportunity or has some human safety data in another indication and/or territory. The firm will generally focus on single therapeutic assets and avoids diagnostics, platforms, and computational biology companies that lack any drug assets.

The firm is open to both lead and co-investing depending on the opportunity. However, typically the firm will not be a lead on a large raise. If the firm creates the company they will be a very active, hands-on investor. The firm is open to investing in very young companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech early stage investment firm headquartered in Taipei, Taiwan invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences investment fund dedicated to accelerating the growth of seed-stage therapeutics companies. In partnership with a family investment office, the firm seeks to make 2-3 new investments by the end of 2020, allocating up to $250,000 per company. The firm invests in companies based in the U.S.

The firm is seeking investments in therapeutics, medical devices, diagnostics and life science tools. For therapeutics companies, the firm prefers treatments for diseases with well-defined etiologies, as well as clear method of action that are in late pre-clinical stage. For diagnostics, device and life science tools, the firm invests in companies that are approaching clearance and/or market launch.

The firm does not have any specific company or management team requirements. The firm is a strategic as well as financial investor, helping companies develop relationships and accelerate growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a global advisory dedicated to healthcare with practices across regulatory and clinical affairs, market access and HEOR strategy consulting, and investment banking uses its experience in the industry to invest in promising early stage companies developing medical devices, diagnostics or digital health technologies. The firm invests at the seed stage, and serves as a strategic investor as much as a financial investor, using industry knowledge and contacts to help companies grow. The firm will generally invest between $250K-1M in companies that have some proof of concept and IP. The firm will invest globally.

The firm invests in medical device, diagnostics and digital health companies. While the firm is generally agnostic to subsector and indication, it tends to avoid companies with a long time to exit. In addition, while the firm is willing to consider all types of medical devices, they are less likely to invest in PMA devices at this stage.

The firm is a very active investor, and thus takes a board seat, even if just an observer position, to lend their expertise. The firm can lead or coinvest, but tends to coinvest, and can help build a syndicate with their contacts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund based in USA leads investments in high growth, mostly US-based Healthcare IT, SaaS, PaaS and technology-enabled service businesses. The firm has a flexible model to right-size equity investments with initial investments typically around $10M. The firm is active in governance and seeks to remain involved through multiple financing rounds. The fund targets a 5-year investment window.

The fund investments are focused on a few key themes in businesses that improve the human condition and deliver value-based care.  It seeks investments in B2B or B2B2C companies with proven business models and experienced teams pursuing end-market opportunities large enough to support creation of companies with $1B in enterprise value. Thematic areas of focus include personalized medicine, patient navigation, referral management, and enablement of payer-provider risk sharing.

The firm is open to work with management teams with various levels of experience. The fund does seek a board seat along with investment and prefers to be fairly involved with the management team and strategy of the company. The fund does not purchase secondary shares of a company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.